{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Wharton Jelly Mesenchymal stem cells",
            "NStudiesAvail": 430108,
            "NStudiesFound": 40,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 40,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Patients will be evaluated for the efficacy of the intracavernous injection of Wharton Jelly derived Mesenchymal Stem Cells by Sexual Health Inventory for Men/International Index of Erectile Function/Erection Hardness Score (SHIM/IIEF/EHS) questionnaire."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaire"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02945449"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "\u2022 Any positive changes in the patient's kidney function in terms of Estimated Gomerular filtration rate (mL/min/1.73 m\u00b2)",
                              "Any positive changes in the patient's kidney function in terms of Urine protein to creatinine ratio."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Evaluation of the preliminary efficacy of the injection on kidney's Estimated Glomerular filtration rate",
                              "Evaluation of the preliminary efficacy of the injection on kidney's protein to creatinine ratio"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03288571"
                        ]
                  },
                  {
                        "Rank": 3,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03751735"
                        ]
                  },
                  {
                        "Rank": 4,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Remission will be considered if reaches 0 points and response if the score diminishes. Endoscopy will be performed at 0 and 12 weeks."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Evaluation of the efficacy of the injected cells (Change from Baseline in partial mayo score)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03299413"
                        ]
                  },
                  {
                        "Rank": 5,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Results of Real-Time Polymerase Chain Reaction of Viral RNA, Turing negative"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "RT-PCR results"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "8 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04313322"
                        ]
                  },
                  {
                        "Rank": 6,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Disease progression assessed in ALSFRS-R scale (Revised Amyotrophic Lateral Sclerosis Functional Rating Scale). Higher scores mean a better outcome.\n\nMinimum: 0 points Maximum: 48 points",
                              "Pulmonary function decline assessed in spirometry (forced vital capacity)",
                              "Muscle strength decline",
                              "Upper motor neuron function assessed in UMNS scale (Upper Motor Neuron Scale). Best outcome 16 points, worst outcomes: 0 points and 48 points Minimum: 0 points Maximum: 48 points",
                              "Cognitive function assessed in ECAS (The Edinburgh Cognitive and Behavioural ALS Screen). Higher scores mean a better outcome.\n\nMinimum: 0 points Maximum: 136 points",
                              "Quality of life changes, assessed by EQ-5D questionnaire - standardized instrument for measuring generic health status. Higher scores mean a better outcome.",
                              "The change of defined cytokines, chemokines, growth factors and pNFH level assessed in the samples of CSF",
                              "The change of defined cytokines, chemokines level assessed in the samples of blood serum",
                              "The change of creatinine and p75ECD level",
                              "Muscle function changes, assessed based on EMG examination (Electrophysiological examination of the muscle - MUNIX - motor unit number estimation)",
                              "The change of the brain visualization in MRI (T1, T2 and DTI)",
                              "The number of SAE/AE and (S)AESI - defined as in Outcome 1",
                              "The number of days from patients randomization to the end of the patients participation in the trial or to the one of the following:\n\nPAV (permanent assisted ventilation)\nTracheostomy\nDeath",
                              "Percentage of deaths in the entire study population."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Disease progression",
                              "Pulmonary function decline",
                              "Muscle strength decline",
                              "Upper motor neuron function",
                              "Cognitive function",
                              "Quality of life changes",
                              "The change of defined cytokines, chemokines, growth factors and pNFH (phosphorylated neurofilament heavy chain) level in CSF (Cerebrospinal fluid)",
                              "The change of defined cytokines, chemokines level in blood",
                              "The change of creatinine and p75ECD level in urine",
                              "Muscle function changes",
                              "The change of the brain visualization",
                              "SAE (Serious Adverse Event)/AE (Adverse Event) and (S)AESI",
                              "Survival period to disease progression",
                              "Mortality rate"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 18 month FU",
                              "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU.",
                              "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU",
                              "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU",
                              "screening and 12 month FU",
                              "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 18 month FU",
                              "run-in visit (-60 day), at baseline and at 1, 2 and 6 month FU (12 month FU optional)",
                              "screening visit, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU.",
                              "screening visit, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU.",
                              "baseline and at 1, 2, 6 and 12 month FU",
                              "run-in visit (-60 day), 6 and 12 month FU",
                              "18 month FU",
                              "18 month FU",
                              "18 month FU"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04651855"
                        ]
                  },
                  {
                        "Rank": 7,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "ASIA Impairment Scale",
                              "Evoked potentials",
                              "Evoked potentials",
                              "Pain threshold perception",
                              "Urodynamic testing",
                              "Anorectal manometry test",
                              "Numerical scale (0 to 10)",
                              "Modified Ashworth scale",
                              "SCIM III scale",
                              "WHOQOL BREF questionnaire",
                              "Qualiveen questionnaire",
                              "Magnetic Resonance Imaging",
                              "Chimerism in cerebrospinal fluid",
                              "Antibodies anti-HLA in peripherical blood and in cerebrospinal fluid"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Extent and severity of a patient's spinal cord injury",
                              "Motor electrophysiology assessment",
                              "Somatosensory electrophysiology assessment",
                              "Electrical nerve stimulation on pain perception",
                              "Mictional dysfunction",
                              "Anal sphincter integrity",
                              "Neuropathic pain",
                              "Spasticity",
                              "Functionality",
                              "Quality of life (individual overall perception of quality of life, individual overall perception of their health, Physical health, Psychological, Social relationships, Environment)",
                              "Urinary disorder",
                              "Size injury",
                              "Presence of allogeneic cells",
                              "Immunology"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months",
                              "6 month",
                              "6 month",
                              "6 month",
                              "6 month",
                              "6 month",
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months",
                              "12 months",
                              "1 month",
                              "1 months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Blood and Tissue Bank of Catalonia",
                              "Hospital de Neurorehabilitaci\u00f3 Institut Guttmann",
                              "Marat\u00f3 TV3"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://bancsang.net/en_index/",
                              "http://www.guttmann.com/en",
                              "http://www.ccma.cat/tv3/marato/en/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03003364"
                        ]
                  },
                  {
                        "Rank": 8,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The efficacy of the intra-articular injection of WJMSC will be assessed by Magnetic Resonance Imaging (MRI)."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Assessment of the efficacy of intra-articular injection of WJMSC"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02963727"
                        ]
                  },
                  {
                        "Rank": 9,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Complete response is defined as a complete resolution of GVHD.",
                              "GVHD will be graded by organ (skin, liver, and gastrointestinal [GI])",
                              "Starting at the day 14 evaluation, if the acute GVHD continues to be unresponsive or worsens, additional agents or changes in immunosuppresive therapy will be at discretion of the Investigator per institutional standards.",
                              "Defined as ectopic tissue formation of greater than 1.0 centimeter (cm) evaluated by comparison CT scan from screening to day 90."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Proportion of participants who achieve a complete response (CR) of aGVHD by study day 42",
                              "Proportion of participants with improvement of GVHD in 1 or more organs involved with GVHD by day 42",
                              "Occurrence of addition of escalated immunosuppressive therapy by day 90",
                              "Occurrence of Formation of ectopic tissue foci at day 90"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "42 days",
                              "42 days",
                              "90 days",
                              "90 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03158896"
                        ]
                  },
                  {
                        "Rank": 10,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The evolution of the PaO2/FiO2 ratio between Day 0 (or Day 1) and Day 14 of treatment with MSC-GW or placebo is a secondary endpoint.",
                              "The effect of WJ-MSC on respiratory assistance is evaluated by the proportion of days without invasive respiratory assistance during the hospital stay and maximum on Day 28 (number of days without invasive respiratory assistance / number of hospital days fixed at day 28)",
                              "Difference in sequential organ failure assessment score (SOFA score), grading 0 (best) to 4 (worst), between Day 5-Day 0 and D14-Day 0",
                              "number of days without extra-renal treatment / number of hospital days fixed at day 28",
                              "number of days without vasopressor support",
                              "The duration of stay in intensive care unit",
                              "Cause of death during the stay in intensive care unit and during the hospital stay, on Day 28 and Day 90",
                              "respiratory morbidity on Day 90",
                              "The evolution of the viral load is evaluated by RT PCR SARS-Cov-2 monitoring on a nasopharyngeal swab (or any other sample) at diagnosis, at Day 7, Day 14, Day 21, Day 28 or on the last day of hospitalisation",
                              "- The anti-HLA antibody rate measured on Day 0 (before initiating treatment), on Day 28 and on Day 90",
                              "The occurrence of immediate hypersensitivity reactions (chills, hyperthermia associated with hypotension) within 4 to 6 hours of the WJ MSC or placebo infusion.",
                              "The thromboembolic risks monitored biologically by routinely daily monitoring of hemostasis (TP, TCA, Fibrinogen, D-dimers)",
                              "daily monitoring of transthoracic echocardiography",
                              "blood cultures in case of T\u00b0 > 38,5\u00b0C"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "respiratory function evolution",
                              "respiratory assistance",
                              "organ failures 1",
                              "organ failures 2",
                              "organ failures 3",
                              "duration of intensive care",
                              "Cause of death",
                              "respiratory morbidity (TDM, functional respiratory measures)",
                              "viral load",
                              "Anti-HLA antibody rate",
                              "immediate hypersensitivity reactions",
                              "thromboembolic adverse events 1",
                              "thromboembolic adverse events 2",
                              "infectious adverse events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "between Day 0 (or Day 1) and Day 14 of treatment",
                              "between day 0 (or 1) and day 28 (or last day of hospitalization if before day 28)",
                              "Day 0 to day 14",
                              "day 0 to day 28",
                              "day 0 to day 28",
                              "day 0 to 90",
                              "day 0 to 90",
                              "day 90",
                              "day 0 to day 28 (or last day of hospitalization if before day 28)",
                              "day 0 to day 90",
                              "day 0, day 3, day 5 (+/- 1day)",
                              "day 0 to day 14",
                              "day 0 to day 14",
                              "day 0 to day 14"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04625738"
                        ]
                  },
                  {
                        "Rank": 11,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Measurement of left ventricular function with echocardiography",
                              "Occurrence of mortality due to cardiovascular causes",
                              "Occurrence of mortality due to cardiovascular causes or heart failure"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in Left Ventricular Function from base line",
                              "Cardiovascular Death",
                              "Composite outcome of cardiovascular death and heart failure incidence"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At baseline and after six months",
                              "Checked at three years",
                              "Checked at three years"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05043610"
                        ]
                  },
                  {
                        "Rank": 12,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "This is the thickness from the outer plexiform layer to the Bruch membrane in the 3x3 mm area of the fovea measured (and recorded automatically) by the multimodal imaging OCTA device."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Outer retinal thickness"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Change from baseline outer retinal thickness at 6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04224207"
                        ]
                  },
                  {
                        "Rank": 13,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Safety evaluation of WJ-MSC describing and comparing incidence, type and severity of adverse events in both groups.",
                              "Evaluation of the effect of WJ-MSC in the time of mechanical ventilation compared between the two groups, as prolonged mechanical ventilation days are associated with higher complication risks as pneumonia, tracheostomy and death.",
                              "Evaluation of the effect of WJ-MSC in the time of hospitalization between the two groups as a measure of efficacy.",
                              "Evaluation of the effect of WJ-MSC in the time of oxygen needs compared between the two groups as a measure of efficacy.",
                              "\"Sequential Organ Failure Assessment\" (SOFA) score is a tool used to determine the beginning and evolution of multiorgan failure, ranging from 0 to 24, being 24 the worst scenario. It has been proven useful as an outcome predictor of mortality and ICU stay. The result is the addition of the evaluation of each organ or system. Effect of WJ-MSC in the SOFA score will be compared between the two groups.",
                              "Murray score is a tool used to classify lung injury. 0 = no lung injury, 0.1-2.5, mild to moderate lund injury, >2.5 Acute respiratory distress syndrome.\n\nThe effect of WJ-MSC in the Murray score will be compared between the two groups.",
                              "APACHE II is a prognostic score based on 12 different items obtained in the first 24 hours of ICU admission. Its mainly used as a single measure, but some authors have used and described prediction usefulness with repeated measures. It ranges from 0 to 71 points. Higher scores are related to higher ICU mortality.\n\nThe effect of WJ-MSC in the APACHE II score will compared between the two groups.",
                              "Evaluation of the effect of WJ-MSC in lymphocyte count measured in absolute number/mm3.\n\nThese laboratory measures have been associated with COVID 19 severity.",
                              "Evaluation of the effect of WJ-MSC in C reactive protein concentration between the two groups, measured in mg/dl.\n\nHighest levels have been associated with COVID 19 severity and inflammation.",
                              "Evaluation of the effect of WJ-MSC in D dimer between the two groups, measured in micrograms Highest levels have been associated with COVID 19 severity and thromboembolic complications.",
                              "Evaluation of the effect of WJ-MSC in ferritin compared between the two groups, measured in nanograms/ml.\n\nThese laboratory measures have been associated with COVID 19 infection and severity.",
                              "Evaluation of the effect of WJ-MSC in LDH compared between the two groups, measured in units/liter.\n\nThese laboratory measures have been associated with COVID 19 infection and severity.",
                              "Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation.The effect of WJ-MSC in IL-6 will be compared between the two groups. It will be measured in picograms/ml.",
                              "Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation. The effect of WJ-MSC in IL 8 will be compared between the two groups. It will be measured in picograms/ml.",
                              "Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation. The effect of WJ-MSC in IL 10 will be compared between the two groups. It will be measured in picograms/ml.",
                              "Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation. The effect of WJ-MSC in TNF alpha will be compared between the two groups. It will be measured in nanograms/ml."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of patients with treatment related adverse events",
                              "Difference in days of mechanical ventilation between groups",
                              "Median reduction of days of hospitalization",
                              "Median reduction of days of oxygen needs",
                              "Difference between \"Sequential Organ Failure Assessment\" score between groups",
                              "Difference between median Murray score between groups",
                              "Difference in APACHE II score between groups",
                              "Difference in lymphocyte count between groups",
                              "Changes in C reactive protein concentration between groups",
                              "Changes in D dimer concentration",
                              "Changes in ferritin concentration",
                              "Changes in lactate dehydrogenase concentration",
                              "Impact on interleukin 6 concentrations between groups.",
                              "Impact on interleukin 8 concentrations between groups.",
                              "Impact on interleukin 10 concentrations between groups.",
                              "Impact on tumor necrosis factor alpha concentrations between groups."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months.",
                              "From ICU admission to 180 days.",
                              "From hospital admission to 180 days.",
                              "From hospital admission to 180 days.",
                              "Baseline to 7 days",
                              "Baseline and 7 days",
                              "Baseline and 7 days",
                              "baseline and 21 days or discharge",
                              "baseline and 21 days or discharge",
                              "baseline and 21 days or discharge",
                              "baseline and 21 days or discharge",
                              "baseline and 21 days or discharge",
                              "Baseline and 7 days",
                              "Baseline and 7 days",
                              "Baseline and 7 days",
                              "Baseline to 7 days."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04390152"
                        ]
                  },
                  {
                        "Rank": 14,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Amplitudes changes in multifocal ERG testing",
                              "Amplitude changes in multifocal ERG testing",
                              "Retinal thickness changes in optical coherence tomography change",
                              "Vascular density changes in optical coherence tomography angiography"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Evaluation of multifocal ERG changes",
                              "Evaluation of ERG changes",
                              "Evaluation of optical coherence tomography changes",
                              "Evaluation of optical coherence tomography angiography changes"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Upto 6 months",
                              "Upto 6 months",
                              "Upto 6 months",
                              "Upto 6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05413148"
                        ]
                  },
                  {
                        "Rank": 15,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Safety will be determined by the assessment of major adverse coronary events (MACE) defined as cardiac death, peri-procedural myocardial infarction, or any repeat coronary intervention at 4 months-1year. Furthermore, safety is also determined by the occurrence of stent thrombosis, arrhythmias events. immune system disorders. The trial will be monitored by a Data and Safety Monitoring Board (DSMB) and the trial will be discontinued in case of safety concerns."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Secondary endpoints: safety will be determined by the assessment of major adverse coronary events (MACE)."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "4 months-1year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01291329"
                        ]
                  },
                  {
                        "Rank": 16,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Defined as any untoward or undesirable medical occurrence in the form of signs, symptoms, abnormal findings, or diseases that emerge or worsen relative to baseline (i.e., if present upon study entry) during the study regardless of causal relationship.\n\nMethods i. Spontaneous subject reports ii. Subject interview by study personnel iii. Clinical examination during face-to-face clinic follow-ups. Defined as any untoward or undesirable medical occurrence in the form of signs, symptoms, abnormal findings, or diseases that emerge or worsen relative to baseline (i.e., if present upon study entry) during the study regardless of causal relationship.\n\nMethods i. Spontaneous subject reports ii. Subject interview by study personnel iii. Clinical examination during face-to-face clinic follow-ups",
                              "Change in radiographic/magnetic resonance joint morphology",
                              "Cartilage thickness on MRI",
                              "Cartilage volume on MRI",
                              "Cartilage morphology on MRI",
                              "Subchondral bone morphology (i.e. edema) on MRI",
                              "Baseline, and 12 months post-treatment cycle based on changes of concentrations of interleukin (IL)-1\u03b2 (pg/ml), IL-6 (pg/ml), IL-8 (pg/ml), IL-11 (pg/ml), CD40L (ng/ml), tumor necrosis factor (TNF)-alpha (pg/ml), high-sensivity C-reactive protein (hsCRP) (mg/dl) and miRNA expression (ug/dl) defined on microarray profilling."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "1. Nature, incidence and severity of adverse events (AEs)",
                              "2. Change in radiographic/magnetic resonance joint morphology",
                              "3. Change in cartilage thickness",
                              "4. Change in cartilage volume",
                              "5. Change in cartilage morphology",
                              "6. Change in subchondral bone morphology",
                              "8. Inflammation monitoring"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline (T0), 3 months (T1), 6 months (T2), 9 months (T3), 12 months (T4), 24 months (T5)",
                              "Baseline, and 12 months post-treatment cycle",
                              "Baseline, and 12 months post-treatment cycle",
                              "Baseline, and 12 months post-treatment cycle",
                              "Baseline, and 12 months post-treatment cycle",
                              "Baseline, and 12 months post-treatment cycle",
                              "Baseline, and 12 months post-treatment cycle]"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03866330"
                        ]
                  },
                  {
                        "Rank": 17,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The secondary end point was efficacy, which was assessed in terms of the change in low attenuation plaque volume LAPV by Coronary computed tomography angiography (coronary CTA) from baseline to 12 months.",
                              "The level of high-sensitivity C-reactive protein (hsCRP) from baseline to 12 months."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The secondary end point was measuring low attenuation plaque volume LAPV",
                              "The secondary end point was efficacy 2"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to 10 months",
                              "up to 10 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04551456"
                        ]
                  },
                  {
                        "Rank": 18,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2018-001964-49"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Safety measured with a combined endpoint of serious clinical events (death or rehospitalization due to any cause) and serious adverse reactions related to the investigational treatment",
                              "Death rate or rehospitalization due to cardiovascular causes at week, 3, 6 and 12 months.",
                              "Rate of relevant arrhythmias in Holter of 24 hours a week, 3 and 12 months.",
                              "Relevant changes in NT-proBNP and hsTnI levels at week, 3 and 12 months.",
                              "Changes in the necrotic myocardial mass ratio due to gadolinium retention at 3 and 12 months.",
                              "change of regional contractility by nuclear magnetic resonance (NMR) at 3 and 12 months.",
                              "Changes in ejection fraction of the left at 3 and 12 months",
                              "changes in left and right ventricular geometric remodeling at 3 and 12 months",
                              "Changes in the score on the quality of life test SF-36 will be used at 3 and 12 months. The m\u00ednimum value is 0 and the m\u00e1ximum value is 100. Higher scores mean a better outcome.",
                              "Changes in the score on the quality of life test KCCQ in cases of participants with heart failure will be used at 3 and 12 months. The test is composed of 23 items. The options for the answers are Likert scales of 1 to 5, 6 or 7 points and the score of each of its dimensions has a theoretical range from 0 to 100, 100 being the best outcome."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Rate of death or rehospitalization due to any cause and / or adverse reactions related to the procedure / product under investigation.",
                              "Death rate or rehospitalization due to cardiovascular causes",
                              "Rate of relevant arrhythmias in Holter of 24 hours",
                              "Relevant changes in N-terminal B-type natriuretic peptide (NT-proBNP) and High sensitivity troponin I (hsTnI) levels",
                              "Changes in the necrotic myocardial mass ratio",
                              "Changes of regional contractility",
                              "Changes in ejection fraction of the left ventricle",
                              "changes in left and right ventricular geometric remodeling",
                              "Changes in the score on the quality of life test Short Form 36 Healthy Survey (SF-36).",
                              "Changes in the score on the quality of life Kansas City Cardiomyopathy Questionnaire (KCCQ) test in cases of participants with heart failure will be used."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At 1 week, 3 and 6 months",
                              "At 1 week, 3 , 6and 12 months",
                              "At 1 week, 3 and 12 months",
                              "At 1 week, 3 and 12 months",
                              "At 3 and 12 months",
                              "At 3 and 12 months",
                              "At 3 and 12 months",
                              "At 3 and 12 months",
                              "At 3 and 12 months",
                              "At 3 and 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03798353"
                        ]
                  },
                  {
                        "Rank": 19,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04432545"
                        ]
                  },
                  {
                        "Rank": 20,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The secondary end point was efficacy, which was assessed in terms of the absolute change in the global LV ejection fraction (LVEF) from baseline to 12 months post-treatment, as measured by cardiac magnetic resonance imaging (CMRI). Furthermore, CMRI assessments measured scar mass and viable myocardial mass in the left ventricle, scar size, cardiac volumes, global function, regional function, and 6-min walk tests in all patients from baseline to 12 months post-treatment."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The secondary end point was efficacy in absolute change of the global LV ejection fraction (LVEF) from baseline to 12 months by MRI"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02368587"
                        ]
                  },
                  {
                        "Rank": 21,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03337243"
                        ]
                  },
                  {
                        "Rank": 22,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02881476"
                        ]
                  },
                  {
                        "Rank": 23,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes in mmHg of Arterial partial pressure of oxygen / Fraction of inspiration O2 (PaO2/FiO2) in all participants",
                              "Changes in percentage of participants with reduction in bilateral ground-glass opacities",
                              "Changes in percentage of participants with reduction of pneumonia bilateral infiltration",
                              "Number of participants with a reduction in Lactate dehydrogenase (mg/dL)",
                              "Number of participants with a reduction in C-reactive protein (mg/dL)",
                              "Number of participants with a reduction in D-dimer (mg/dL)",
                              "Number of participants with a reduction in Ferritine (mg/dL)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Oxygen pressure in inspiration",
                              "ground-glass opacity",
                              "Pneumonia infiltration",
                              "Lactate dehydrogenase",
                              "C-reactive protein",
                              "D-dimer",
                              "Ferritine"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, and at days 2, 4 and 14 post-treatment",
                              "Baseline, and at day 14 post-treatment",
                              "Baseline, and at day 14 post-treatment",
                              "Baseline, and at days 4 and 14 post-treatment",
                              "Baseline, and at days 4 and 14 post-treatment",
                              "Baseline, and at days 4 and 14 post-treatment",
                              "Baseline, and at days 4 and 14 post-treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04456361"
                        ]
                  },
                  {
                        "Rank": 24,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Recovery of the estimated functional status according to the New York Heart Association (NYHA) classification",
                              "Change in the median score for quality of life of the Minnesota Living with Heart Failure Questionnaire (MLHFQ)",
                              "Changes in the delayed enhancement of the left ventricle on MRI, defined as percentage of the wall thickness involved when adding each segment visually",
                              "Improvement in the 6-minute walk test, defined as the percentage of change of the distance traveled",
                              "Mortality at 3 and 12 months due to cardiovascular causes",
                              "Mortality at 3 and 12 months due to all causes"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Estimated functional status",
                              "Change in the median score of Quality of life",
                              "Delayed enhancement of the left ventricle",
                              "Improvement in the 6-minute walk test",
                              "Mortality at 3 and 12 months due to cardiovascular causes",
                              "Mortality at 3 and 12 months due to all causes"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04011059"
                        ]
                  },
                  {
                        "Rank": 25,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change in the ODI at 1, 3, 6, 9, and 12 months after the transplantation of WJ-MSCs, compared to before the transplantation.\n\non a scale of 0 to 3, with 0 meaning no disability and 10 meaning severe disability",
                              "Change in the T score (lumbar spine and femoral neck) of dual-energy x-ray absorptiometry at 6 and 12 months after the transplantation compared to before the transplantation",
                              "identification of spine fracture based on x ray",
                              "Change in the bone mineral density (computed tomography) at 6 and 12 months after the transplantation compared to before the transplantation"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "improvement in Oswestry Disability Index",
                              "Change in the T score (lumbar spine and femoral neck) of dual-energy x-ray absorptiometry",
                              "Presence of new vertebral fracture",
                              "Change in the bone mineral density (computed tomography) of fractured vertebrae"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05018637"
                        ]
                  },
                  {
                        "Rank": 26,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "FPDI was examined in the 24/2 visual field of the computerized perimetry records. The FPDI offers data explaining how many of the 100 flashing points and what percentage of the visual field could be correctly seen by the patient. For VF analysis, in order to avoid mistakes during the test, practice rounds were carried out three times before applications.",
                              "GCC is the thickness from the internal limiting membrane to the inner plexiform layer in the 3x3 mm of foveal area. The measurement done automatically by the OCTA device. GCC is the total thickness of the ganglion cells and retinal nerve fibers.",
                              "pVEP is a objective test that measures the electrical activity of the optical pathway in response to a light stimulus. The 120' patterns reveals responses from the all retinal quadrants. The measurements were taken according to the ISCEV standarts for both eyes. We used the 120'pattern VEP protocol, which combines p100 implicit time and amplitude, to create a numerical result."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Visual field sensitivity: Fundus perimetry deviation index (FPDI, %)",
                              "Ganglion cell complex thickness (GCC thickness, \u00b5m):",
                              "Pattern visual evoked potential (pVEP)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Change from baseline FPDI at 3 months",
                              "Change from baseline GCC thickness at 3 months",
                              "Change from baseline p100 latency and amolitude at 3 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04877067"
                        ]
                  },
                  {
                        "Rank": 27,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Infarct size reduction in SPECT.",
                              "Myocardial perfusion improvement assessed in SPECT.",
                              "Myocardial perfusion improvement assessed in cardiac MRI.",
                              "Increase of left ventricle ejection fraction (LVEF) assessed in cardiac MRI.",
                              "Increase of left ventricle ejection fraction (LVEF) assessed in SPECT.",
                              "Left ventricle ejection fraction (LVEF) change (in %) against baseline, assessed in echocardiography.",
                              "Left ventricle end-systolic volume (ESV, in ml) change against baseline, assessed in echocardiography",
                              "Left ventricle end-diastolic volume (EDV, in ml) change against baseline, assessed in echocardiography.",
                              "The occurrence of major adverse cardiovascular events (MACE including death, myocardial infarction, and hospitalization for heart failure).",
                              "Quality of life improvement, assessed by SF-36 questionnaire or other dedicated for investigated population."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Infarct size reduction",
                              "Myocardial perfusion improvement",
                              "Myocardial perfusion improvement",
                              "Increase of left ventricle ejection fraction (LVEF)",
                              "Increase of left ventricle ejection fraction (LVEF)",
                              "Left ventricle ejection fraction (LVEF) change against baseline.",
                              "Left ventricle end-systolic volume (ESV) change against baseline.",
                              "Left ventricle end-diastolic volume (EDV) change against baseline.",
                              "The occurrence of major adverse cardiovascular events",
                              "Quality of life improvement"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "1 year FU",
                              "6 month and 1 year FU."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03404063"
                        ]
                  },
                  {
                        "Rank": 28,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03529136"
                        ]
                  },
                  {
                        "Rank": 29,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Number of patients with treatment-emergent adverse events, by treatment group",
                              "Number of patients who, after the start of treatment, required rescue medication, by treatment group",
                              "Number of days that the patient requires invasive mechanical ventilation from the start of treatment to day +28, by treatment group",
                              "Days after treatment in which the patient remains alive and free of invasive mechanical ventilation, per treatment group.",
                              "Variation of the oxygenation index (PaO2 / FiO2) with respect to the baseline value, by treatment group.",
                              "Variation of the score of the Sequential Organ Failure Assessment (SOFA) Index with respect to the baseline value, by treatment group.",
                              "Variation of Acute Physiology and Chronic Health disease Classification System II (APACHE II) score, by treatment group.",
                              "Days of stay in the ICU from the day of admission until discharge to day 28, or date of death if earlier, by treatment group.",
                              "Variation in the count and percentage of leukocytes and neutrophils, by treatment group.",
                              "Feasibility will be evaluated by the time elapsed from the request of the treatment by the hospital center until the delivery date",
                              "Feasibility will be evaluated by the number of patients treated within 2 days of the request for treatment.",
                              "Variation in the values of the biomarker, by treatment group.",
                              "Variation in the values of the biomarker, by treatment group.",
                              "Variation in the values of the biomarker, by treatment group.",
                              "Variation in the values of the biomarker, by treatment group."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Safety of WJ-MSC",
                              "Need for treatment with rescue medication",
                              "Need and duration of mechanical ventilation",
                              "Ventilator free days",
                              "Evolution of PaO2 / FiO2 ratio",
                              "Evolution of the SOFA index",
                              "Evolution of the APACHE II score",
                              "Duration of hospitalization",
                              "Evolution of markers of immune response (leucocyte count, neutrophils)",
                              "Feasibility of WJ-MSC administration",
                              "Feasibility of WJ-MSC administration",
                              "Evolution of disease biomarker: polymerase chain reaction (RT-PCR)",
                              "Evolution of disease biomarker: lactate dehydrogenase (LDH)",
                              "Evolution of disease biomarker: D-dimer",
                              "Evolution of disease biomarker: Ferritin"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Blood and Tissue Bank of Catalonia",
                              "Hospital Cl\u00ednic de Barcelona",
                              "Hospital Vall d'Hebron",
                              "Hospital del Mar",
                              "M\u00fatua de Terrassa",
                              "Hospital de Bellvitge"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.bancsang.net",
                              "http://www.clinicbarcelona.org",
                              "http://www.vallhebron.com",
                              "http://www.parcdesalutmar.cat",
                              "http://www.mutuaterrassa.com",
                              "http://bellvitgehospital.cat"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04390139"
                        ]
                  },
                  {
                        "Rank": 30,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Secondary end points included death from a composite of major adverse card cardiovascular events plus any coronary revascularization within 12 months.",
                              "Secondary end points included death from hospitalization for congestive heart failure within 12 months.",
                              "Secondary end points included the level change of hsCRP within 12 months."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Coronary disease",
                              "Coronary congestive heart failure",
                              "Coronary changes in hsCRP"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04551443"
                        ]
                  },
                  {
                        "Rank": 31,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Non-Probability Sample"
                        ],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05093725"
                        ]
                  },
                  {
                        "Rank": 32,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Probability Sample"
                        ],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Use the decellularized matrix for tissue regeneration purposes, it should be able to support recellularization with undifferentiated mesenchymal stem cells and help support their differentiation into different tissues, including bone or cartilage."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Study the ability of the isolated and decellularized matrix to support recellularization with mesenchymal stem cells and to support their growth and differentiation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Within 24 hours"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01166776"
                        ]
                  },
                  {
                        "Rank": 33,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04863183"
                        ]
                  },
                  {
                        "Rank": 34,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [
                              "Immune characterization of mesenchymal stem cells in human umbilical cord Wharton's jelly and derived cartilage cells",
                              "Evidence-based management strategies for treatment of chronic wounds",
                              "Long-Term Expansion and Pluripotent Marker Array Analysis of Wharton's Jelly-Derived Mesenchymal Stem Cells"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://dx.doi.org/10.1016/j.cellimm.2012.06.010",
                              "http://www.liebertpub.com/doi/10.1089/wound.2012.0381",
                              "http://www.liebertonline.com/doi/abs/10.1089/scd.2009.0177"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04134676"
                        ]
                  },
                  {
                        "Rank": 35,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2020-001287-28"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Lung injury score",
                              "Oxygenation index",
                              "In-hospital mortality",
                              "Mortality",
                              "Ventilator-free days",
                              "Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 > 200 (out of a prone positioning session)",
                              "Cumulative use of sedatives",
                              "Cumulative duration of use of sedatives",
                              "Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)",
                              "Cumulative use of neuromuscular blocking agents (other than used for intubation)",
                              "ICU-acquired weakness and delirium",
                              "Treatment-induced toxicity rate and adverse events up to day 28",
                              "Quality of life at one year (EQ5D-3L quality of life questionnaire)",
                              "Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level",
                              "Anti-HLA antibodies plasmatic dosage"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "At day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "From baseline to day 28",
                              "At 6 months and 12 months",
                              "At day 1, 3, 5, 7 and 14",
                              "From baseline to day 14, and at 6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04333368"
                        ]
                  },
                  {
                        "Rank": 36,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04288934"
                        ]
                  },
                  {
                        "Rank": 37,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Probability Sample"
                        ],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03562715"
                        ]
                  },
                  {
                        "Rank": 38,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change in Patient-Reported Outcomes Measurement Information System (PROMIS29) scores",
                              "Number of participants evaluated by X-ray and MRI of knee OA from baseline Kellegren-Lawrence grading system.",
                              "Changes of interleukins (IL-1b, IL-6, PGE-2, TGF-b, TNF-a, IGF-1) of articular cavity fluid from baseline to week 12"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "PROMIS29 score",
                              "Kellegren-Lawrence grading",
                              "Interleukins"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04520945"
                        ]
                  },
                  {
                        "Rank": 39,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "An increase the result of 6 minute walk test at 3 and 6 month.",
                              "Myocardial perfusion improvement assessed in SPECT at 6 month FU.",
                              "Myocardial perfusion improvement assessed in cardiac MRI at 6 month FU.",
                              "An improvement the result of spiroergometric test at 6 month FU.",
                              "Left ventricle ejection fraction (LVEF) change (in %) against baseline, assessed in echocardiography.",
                              "Left ventricle end-systolic volume (ESV, in ml) change against baseline, assessed in echocardiography.",
                              "Left ventricle end-diastolic volume (EDV, in ml) change against baseline, assessed in echocardiography.",
                              "NT pro-BNP level at 3, 6 and 12 months in comparison to the baseline level.",
                              "The occurrence of major adverse cardiovascular events (MACE including death, myocardial infarction, and hospitalization for heart failure) at 6 month and 1 year FU.",
                              "Quality of life improvement, assessed by SF-36 questionnaire or other dedicated for investigated population at 6 month and 1 year FU."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "An increase the result of 6 minute walk test",
                              "Myocardial perfusion improvement",
                              "Myocardial perfusion improvement",
                              "An improvement the result of spiroergometric test",
                              "Left ventricle ejection fraction (LVEF) change against baseline",
                              "Left ventricle end-systolic volume (ESV) change against baseline",
                              "Left ventricle end-diastolic volume (EDV) change against baseline",
                              "NT pro-BNP level",
                              "The occurrence of major adverse cardiovascular events",
                              "Quality of life improvement"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 and 6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "3, 6 and 12 months FU",
                              "6 month and 1 year FU",
                              "6 month and 1 year FU"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03418233"
                        ]
                  },
                  {
                        "Rank": 40,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Amputation-free survival period evaluation of treated leg at 6 month and 1 year FU.",
                              "Ulcer-free survival (in patients without ulceration at baseline evaluation) of treated leg in period evaluation at 6 month and 1 year FU.",
                              "Ulcer-extension free survival (in patients with ulceration in the beginning of the trial) of treated leg in period evaluation at 6 month and 1 year FU.",
                              "Change in tissue oxygen/CO2 tension, assessed by NIRS method at each trial evaluation point.",
                              "An improvement of tissue perfusion assessed in MRI at each trial evaluation point.",
                              "Change in transcutaneous pressure of O2 (tcpO2) between two groups (active vs placebo therapy) at each trial evaluation point.",
                              "Change in ABI score at each trial evaluation point.\n\nThe ankle-brachial index (ABI) is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm and is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressure in the arm.\n\nAn ABI between and including 0.9 and 1.2 is considered normal, while a lesser than 0.9 indicates peripheral arterial disease. An ABI value of 1.3 or greater is also considered abnormal, and suggests calcification of the walls of the arteries and incompressible vessels. ABI score progression towards the normal range is considered as a better outcome.",
                              "Quality of life improvement, assessed by SF-36 questionnaire or other dedicated for investigated population at each trial evaluation point."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Amputation-free survival period",
                              "Ulcer-free survival",
                              "Ulcer-extension free survival",
                              "Change in tissue oxygen/CO2 tension",
                              "An improvement of tissue perfusion",
                              "Change in transcutaneous pressure of O2",
                              "Change in ABI score",
                              "Quality of life improvement, assessed by SF-36 questionnaire"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 month and 1 year FU.",
                              "6 month and 1 year FU",
                              "6 month and 1 year FU",
                              "45 days, 3 month, 6 month and 1 year FU",
                              "45 days, 3 month, 6 month and 1 year FU",
                              "45 days, 3 month, 6 month and 1 year FU",
                              "45 days, 3 month, 6 month and 1 year FU",
                              "45 days, 3 month, 6 month and 1 year FU"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03423732"
                        ]
                  }
            ]
      }
}